OVARIAN CARCINOSARCOMA
Clinical trials for OVARIAN CARCINOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN CARCINOSARCOMA trials appear
Sign up with your email to follow new studies for OVARIAN CARCINOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New radioactive drug targets FAP-Positive tumors in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …
Matched conditions: OVARIAN CARCINOSARCOMA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for rare, deadly gynecologic cancers: drug combo trial launches
Disease control Recruiting nowThis clinical trial is testing whether a combination of two drugs—dostarlimab (an immunotherapy) and niraparib (a PARP inhibitor)—works better than standard chemotherapy for women with a rare and aggressive type of uterine or ovarian cancer called carcinosarcoma. The study will e…
Matched conditions: OVARIAN CARCINOSARCOMA
Phase: PHASE2, PHASE3 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to control ovarian cancer and reduce painful fluid buildup
Disease control Recruiting nowThis study tests whether adding an experimental drug (APL-2) to standard immunotherapy (pembrolizumab) and/or a targeted therapy (bevacizumab) can better control recurrent ovarian, fallopian tube, or peritoneal cancer that causes fluid buildup in the belly or chest. About 60 adul…
Matched conditions: OVARIAN CARCINOSARCOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New pill takes on tough cancers: early trial launches
Disease control Recruiting nowThis study tests a new daily pill, VLS-1488, for people with advanced solid tumors that have not responded to other treatments. About 200 participants with specific cancers like ovarian, lung, or breast cancer will receive the drug to see if it is safe and shrinks tumors. The goa…
Matched conditions: OVARIAN CARCINOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Volastra Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC